A PILOT STUDY ON UTILIZATION PATTERN OF ANTIPSYCHOTIC DRUGS IN SCHIZOPHRENIC PATIENTS FROM SOUTHERN INDIA

2017 ◽  
pp. 1301-1308
Author(s):  
S. Sridhar
Keyword(s):  
Pilot Study ◽  
Antipsychotic Drugs ◽  
Southern India ◽  
Utilization Pattern ◽  
Schizophrenic Patients

Gene Frequency of CYP2D6*4 and *10 Variants in Karachi Population

2020 ◽  
Vol 17 ◽  
Author(s):  
Tamkeen Fatima ◽  
Farah Zeb ◽  
A. Dar Farooq
Keyword(s):  
Antipsychotic Drugs ◽  
Screening Program ◽  
Restriction Enzymes ◽  
Normal Subjects ◽  
Control Group ◽  
Poor Metabolizer ◽  
Cyp2d6 Polymorphism ◽  
Wild Allele ◽  
Schizophrenic Patients ◽  
Intermediate Metabolizer

Background: CYP2D6 is to be considered the most pronounced gene in pharmacegenetic field which is involved in metabolizing ~25% of all clinically used neuroleptic drugs and other antidepressants. We designed a study to evaluate differential expression of CYP2D6*4 and CYP2D6*10 variants which are very prevalent in Asian countries and exhibit variation in drug metabolizing ability that affect therapeutic responses. Objective: The purpose of this study is to determine the genotypic frequencies of CYP2D6 *1 (normal metabolizer), *4 (poor metabolizer) and *10 (intermediate metabolizer) variants among schizophrenic subjects and compared with control group from a sub-set of Karachi population. Method: Genomic deoxyribonucleic acid (DNA ) was extracted and amplified with CYP2D6*4 and *10 primers using polymerase chain reaction (PCR) and digested by Bacillus stereothermophilus (BstN1) and Hemophilus parahemolyticus (Hph1) restriction enzymes. The digested bands were identified as wild type or mutants and their genotypic frequencies were estimated statistically by Hardy-Weinberg equation (HWE) and analyzed further under non-parametric Chi-square test. Results: The results mentioned the frequencies of CYP2D6*1 wild allele (57%) which produces functional enzyme in normal subjects but CYP2D6*4 variant (9%) that produces non-functional enzyme and CYP2D6*10 allele (70%) produces altered enzyme with reduced activity that was most prevalent in schizophrenic patients. Conclusion : Genotyping of CYP2D6 alleles among schizophrenic patients indicated prevalence of *4 and *10 variants in Karachi population producing non-functional and reduced functional drugs metabolizing enzymes respectively that increases the incurability rate of schizophrenia. Therefore, CYP2D6 gene screening program should be conducted routinely in clinical practice to help clinicians to prescribing appropriate doses according to patient’s genotype and minimize the sufferings of schizophrenia. Discussion: In last, drug response is a complex phenomenon that is dependent on genetic and environmental factors. CYP2D6 polymorphism may un-cured the schizophrenia due to improper drug metabolism and protein-proteins interaction that may alter the antipsychotic drugs metabolism among patients with variable drug resposes. Gene testing system need to establish for analyzing maximum patient’s genotypes predicted with poor metabolizer, intermediate metabolizer and ultrarapid metabolizer for the adjustment of antipsychotic drugs.

The management of tardive dyskinesia

1986 ◽  
Vol 24 (7) ◽  
pp. 27-28
Keyword(s):  
Tardive Dyskinesia ◽  
Antipsychotic Drugs ◽  
Disease Process ◽  
Neuroleptic Drug ◽  
Blocking Drug ◽  
Unwanted Effect ◽  
Difficult Condition ◽  
The Face ◽  
Schizophrenic Patients

Dyskinesias are involuntary movements usually of the face and tongue and sometimes of the limbs and trunk. Tardive (delayed) dyskinesia occurs in patients who have been taking an antipsychotic (neuroleptic) drug or, rarely, another central dopamine-receptor-blocking drug such as metoclopramide. It generally occurs only in those treated for longer than a year, although much shorter exposures have been implicated with the antipsychotics. A similar dyskinesia occurred in schizophrenic patients before antipsychotic drugs were introduced, and can occur in healthy untreated elderly people; risk factors include old age, brain damage1 and the schizophrenic disease process.2 Nevertheless, in most patients on an antipsychotic drug (whether psychotic or not), tardive dyskinesia is an unwanted effect of the drug. It occurs in 5–40% of patients on long-term antipsychotic medication.3–5 we discuss here advances in the management of this difficult condition since our last review.6

scholarly journals Prevalence of Sexual Dysfunction in Schizophrenic Patients Taking Antipsychotic Drugs

2016 ◽  
Vol 19 (2) ◽  
pp. 60
Author(s):  
Sun Hwa Jeong ◽  
Shi Hyun Kang ◽  
Dong Yeon Park ◽  
Hai Joo Yoon ◽  
Eun Kyung Park ◽  
...  
Keyword(s):  
Sexual Dysfunction ◽  
Antipsychotic Drugs ◽  
Schizophrenic Patients

Enhanced calcium responses to serotonin receptor stimulation in T-lymphocytes from schizophrenic patients – A pilot study

2015 ◽  
Vol 589 ◽  
pp. 159-162 ◽  
Author(s):  
J. Genius ◽  
A. Schellenberg ◽  
L. Tchana-Duope ◽  
N. Hartmann ◽  
I. Giegling ◽  
...  
Keyword(s):  
Pilot Study ◽  
T Lymphocytes ◽  
Serotonin Receptor ◽  
Receptor Stimulation ◽  
Schizophrenic Patients

Slow parasite clearance, absent K13-propeller gene polymorphisms and adequate artesunate levels among patients with malaria: A pilot study from southern India

2019 ◽  
Vol 32 (4) ◽  
pp. 200
Author(s):  
Priscilla Rupali ◽  
TAngel Miraclin ◽  
BinuSusan Mathew ◽  
JoyJohn Mammen ◽  
ShajiV Ramachandran ◽  
...  
Keyword(s):  
Pilot Study ◽  
Gene Polymorphisms ◽  
Parasite Clearance ◽  
Southern India

scholarly journals A CASE STUDY ON SCHIZOPHRENIA INDUCED MULTIPLE COMORBIDITIES

2018 ◽  
Vol 11 (6) ◽  
pp. 1
Author(s):  
Jagadeesan M ◽  
Kiran Kumar R ◽  
Justin Jacob Abraham
Keyword(s):  
Diabetes Mellitus ◽  
Metabolic Syndrome ◽  
Antipsychotic Drugs ◽  
Hypoglycemic Agents ◽  
Systemic Hypertension ◽  
Inferior Wall ◽  
Cardiovascular Risks ◽  
Coronary Syndrome ◽  
Schizophrenic Patients

Schizophrenia is a mental disorder characterized by abnormal social behavior which includes false beliefs, confusion, and auditory hallucination. Antipsychotic drugs therapy increases the risk of developing diabetes mellitus and coronary artery disease (CAD) in schizophrenic patients. Hence, we have planned for a systematic approach toward the management of comorbidities induced in schizophrenic patients. A case study was conducted in 42-year-old female patient diagnosed with schizophrenia along with Type-2 diabetes mellitus, hypothyroidism, diabetic retinopathy, diabetic nephropathy, systemic hypertension, CAD-acute coronary syndrome recent inferior wall myocardial infarction. The patient was treated with atypical antipsychotics, antiplatelets, antianginals, statins, hypoglycemic agents, and other supportive measures. The patient improved symptomatically. The antipsychotic treatment for schizophrenia induces abnormal metabolic syndrome which results in decreased glucose and lipid metabolism that leads to obesity, hyperglycemia, and dyslipidemia associated with cardiovascular risks. Often antipsychotics are combined with benzodiazepines and antiparkinson agents to reduce the risks caused from large doses of antipsychotic medication. However, people receiving first-generation antipsychotics have higher prevalence of developing diabetes mellitus and cardiac risks compared to second-generation antipsychotics. Hence, we conclude that atypical antipsychotic drugs such as amisulpride, aripiprazole, and ziprasidone should be given to schizophrenic patients because these drugs have little effects on abnormal metabolic syndrome when compared to other antipsychotics. There is a need for proper screening of blood glucose level and cardiovascular risks assessment before the administration of antipsychotic medications to schizophrenic patients and also during the course of treatment regularly.

Responsiveness of subjective quality of life assessment in schizophrenic patients: a quasi-experimental pilot study

2001 ◽  
Vol 16 (2) ◽  
pp. 99-103 ◽  
Author(s):  
M. Franz ◽  
T. Meyer ◽  
A. Spitznagel ◽  
H. Schmidt ◽  
K. Wening ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Pilot Study ◽  
High Stability ◽  
Life Assessment ◽  
Subjective Quality Of Life ◽  
Quality Of Life Assessment ◽  
Quasi Experimental ◽  
Schizophrenic Patients ◽  
Time Point

Responsiveness of quality of life (QOL) assessments in chronic schizophrenic patients was investigated by a quasi-experimental pilot study. Satisfaction ratings were assessed over five time points with an externally imposed disturbing stimulus at the second time point. Despite a markedly high stability, the disturbance provoked a temporally limited decrease in QOL.

Sign in / Sign up

Export Citation Format

Share Document